Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 302 of 302

TitleReference numberPublishedLast updated
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Relugolix for treating hormone-sensitive prostate cancerTA995
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Ovarian cancer: identifying and managing familial and genetic riskNG241
Lung cancer: diagnosis and managementNG122
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Skin cancerQS130
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Ovarian cancer: recognition and initial managementCG122
Suspected cancer: recognition and referralNG12
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary careDG56
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Irreversible electroporation for treating prostate cancerIPG768
Oesophago-gastric cancer: assessment and management in adultsNG83
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerIPG763
Transperineal biopsy for diagnosing prostate cancerDG54
MRI fusion biopsy systems for diagnosing prostate cancerDG53
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Focal therapy using high-intensity focused ultrasound for localised prostate cancerIPG756
Maximal cytoreductive surgery for advanced ovarian cancerIPG757
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Regorafenib for previously treated metastatic colorectal cancerTA866
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerIPG752
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Thyroid cancer: assessment and managementNG230
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerMTG72
Signatera for detecting molecular residual disease from solid tumour cancersMIB307
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Contrast-enhanced spectral mammography for breast cancerMIB304
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Stockholm3 for prostate cancer screeningMIB303
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Bladder EpiCheck for detecting bladder cancer recurrenceMIB293
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodulesDG46
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Microwave ablation for primary or metastatic cancer in the lungIPG716
Colorectal cancerQS20
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Prostate cancerQS91
Transanal total mesorectal excision for rectal cancerIPG713
Colorectal cancerNG151
Prostate cancer: diagnosis and managementNG131
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Synergo for non-muscle-invasive bladder cancerMTG61
Paige Prostate for prostate cancerMIB280
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Selpercatinib for treating advanced thyroid cancer with RET alterationsTA742
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancerTA721
Immunoscore for predicting risk of colon cancer relapseMIB269
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
trublood-prostate for triaging and diagnosing people with prostate cancer symptomsMIB268
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverIPG691
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
URO17 for detecting bladder cancerMIB250
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Minimally invasive radical hysterectomy for early stage cervical cancerIPG686
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerTA660
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Magseed for locating impalpable breast cancer lesionsMIB236
Testing strategies for Lynch syndrome in people with endometrial cancerDG42
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Archimedes for biopsy of suspected lung cancerMIB211
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lung cancer in adultsQS17
Irreversible electroporation for primary liver cancerIPG664
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancerIPG659
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancerIPG656
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
ADXBLADDER for detecting bladder cancerMIB180
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Axumin for functional imaging of prostate cancer recurrenceMIB172
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancerIPG638
Pancreatic cancerQS177
Oesophago-gastric cancerQS176
Vandetanib for treating medullary thyroid cancerTA550
Padeliporfin for untreated localised prostate cancerTA546
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancerIPG628
AlignRT in breast cancer radiotherapyMIB157
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapyTA530
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and overNG36
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
ColonFlag for identifying people at risk of colorectal cancerMIB142
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Cabozantinib for treating medullary thyroid cancerTA516
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Pancreatic cancer in adults: diagnosis and managementNG85
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
MammaTyper in vitro diagnostic test for determining breast cancer subtypesMIB135
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancerMIB137
Next-generation sequencing panel for solid tumour cancers in childrenMIB133
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Suspected cancerQS124
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Tests in secondary care to identify people at high risk of ovarian cancerDG31
HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancerMIB128
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Caris Molecular Intelligence for guiding cancer treatmentMIB120
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerTA476
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Advanced breast cancer: diagnosis and treatmentCG81
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
L-Dex U400 for lymphoedema after breast cancer treatmentMIB111
Haematological cancersQS150
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Irreversible electroporation for treating pancreatic cancerIPG579
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Head and neck cancerQS146
Molecular testing strategies for Lynch syndrome in people with colorectal cancerDG27
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Axxent electronic brachytherapy system for early stage breast cancerMIB76
OSNA for colon cancer stagingMIB77
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Breast cancerQS12
Haematological cancers: improving outcomesNG47
Prolaris gene expression assay for assessing long-term risk of prostate cancer progressionMIB65
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancerTA389
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)TA23
Skin cancer preventionPH32
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA377
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyTA378
Bladder cancerQS106
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesionsDG19
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancerIPG532
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Preoperative high dose rate brachytherapy for rectal cancerIPG531
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancerTA347
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Bladder cancer: diagnosis and managementNG2
The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancerMIB16
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapyTA323
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Cancer services for children and young peopleQS55
Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatmentESUOM21
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancerDG9
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancerDG8
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumabESNM13
Irreversible electroporation for treating primary lung cancer and metastases in the lungIPG441
Irreversible electroporation for treating renal cancerIPG443
Neutropenic sepsis: prevention and management in people with cancerCG151
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2TA257
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Ovarian cancerQS18
Focal therapy using cryoablation for localised prostate cancerIPG423
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Breast reconstruction using lipomodelling after breast cancer treatmentIPG417
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Laparoscopic cryotherapy for renal cancerIPG405
Percutaneous cryotherapy for renal cancerIPG402
Ambulight PDT for the treatment of non-melanoma skin cancerMTG6
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancerTA227
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Percutaneous radiofrequency ablation for primary or secondary lung cancersIPG372
Trastuzumab for the treatment of HER2-positive metastatic gastric cancerTA208
Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancerIPG356
Capecitabine for the treatment of advanced gastric cancerTA191
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Percutaneous radiofrequency ablation for renal cancerIPG353
Topotecan for the treatment of relapsed small-cell lung cancerTA184
Topotecan for the treatment of recurrent and stage IVB cervical cancerTA183
Pemetrexed for the first-line treatment of non-small-cell lung cancerTA181
Ex-vivo hepatic resection and reimplantation for liver cancerIPG298
Endoscopic mastectomy and endoscopic wide local excision for breast cancerIPG296
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excisionIPG268
Laparoscopic gastrectomy for cancerIPG269
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neckTA145
Pemetrexed for the treatment of non-small-cell lung cancerTA124
Gemcitabine for the treatment of metastatic breast cancerTA116
Palliative photodynamic therapy for advanced oesophageal cancerIPG206
Photodynamic therapy for early-stage oesophageal cancerIPG200
Laparoscopic surgery for colorectal cancerTA105
Docetaxel for the treatment of hormone-refractory metastatic prostate cancerTA101
High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancerIPG174
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancerTA100
Laparoscopic retroperitoneal lymph node dissection for testicular cancerIPG158
Endoscopic axillary lymph node retrieval for breast cancerIPG147
Photodynamic therapy for localised inoperable endobronchial cancerIPG137
Cryotherapy as a primary treatment for prostate cancerIPG145
Improving outcomes in children and young people with cancerCSG7
Low dose rate brachytherapy for localised prostate cancerIPG132
Photodynamic therapy for bile duct cancerIPG134
Cryotherapy for recurrent prostate cancerIPG119
Guidance on the use of paclitaxel in the treatment of ovarian cancerTA55
High-intensity focused ultrasound for prostate cancerIPG118
Improving outcomes in head and neck cancersCSG6
Interstitial laser therapy for breast cancerIPG89
Improving supportive and palliative care for adults with cancerCSG4
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancerTA61
Improving outcomes in urological cancersCSG2
Improving outcomes in breast cancerCSG1
Guidance on the use of trastuzumab for the treatment of advanced breast cancerTA34

Results per page

  1. 10
  2. 25
  3. 50
  4. All